Apimeds Pharmaceuticals US (APUS) Payables (2023 - 2025)

Apimeds Pharmaceuticals US has reported Payables for 3 years, with the latest figure at $8.0 million in Q4 2025.

• For the quarter ending Q4 2025, Payables rose 852.21% year-over-year to $8.0 million; the trailing twelve-month figure through Dec 2025 stood at $8.0 million (up 852.21% YoY), and the FY2025 full-year result was $8.0 million, up 852.21% from the prior year.
• Payables for Q4 2025 stood at $8.0 million, up from $567633.0 in the prior quarter.
• The five-year high for Payables was $8.0 million in Q4 2025, with the low at $119138.0 in Q2 2025.
• Historically, Payables has averaged $1.9 million across 3 years, with a median of $704412.0 in 2024.
• Annual changes were most pronounced in 2024 — Payables soared 161.78% — and 2025, when it soared 852.21%.
• Apimeds Pharmaceuticals US's Payables stood at $321329.0 in 2023, then surged by 161.78% to $841191.0 in 2024, then soared by 852.21% to $8.0 million in 2025.
• The last three Payables figures came in at $8.0 million (Q4 2025), $567633.0 (Q3 2025), and $119138.0 (Q2 2025), per Business Quant data.